More on PMN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $13.30 |
|
|||
| Open | $12.99 | ||||
| 52 Wk High | $0.05 | ||||
| 52 Wk Low | $0.05 | ||||
| Day High | $15.85 | ||||
| Day Low | $12.91 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 132,985 | ||||
- H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)
- ProMIS reports human evidence of PMN310 reducing amyloid-beta oligomers
- ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
- Roth/MKM Starts ProMIS Neurosciences (PMN) at Buy
- Cantor Fitzgerald Starts ProMIS Neurosciences (PMN) at Overweight
- H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)
- H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)
- Form S-8 ProMIS Neurosciences
- ProMIS Neurosciences to Participate in Upcoming Conferences in June
- Form 4 ProMIS Neurosciences For: May 20 Filed by: WYMAN WILLIAM W
Entities mentioned with PMN
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- FDA | View Related Stories »
- S1 | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
